Business Daily Media

Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory

BEIJING, CHINA - Media OutReach - 6 June 2022 - Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that it has completed a $60 million Series D financing from a syndicate of global investors with expertise in investing in the biopharmaceutical and life sciences sectors.

The financing comprised a mix of new investors, including a large, diversified asset management firm on the US West Coast and BHR Partners, along with current investors, including Warburg Pincus, B Capital Group, Qiming Venture Partners, BOLD Capital Partners and Pavilion Capital. Insilico’s founder and CEO, Alex Zhavoronkov, PhD, also invested in the Series D round.

Capital raised in the round will further bolster Insilico’s financial position and fuel the growth of its advancing pipeline, including its lead program which is currently in a Phase I study, and continued development of its Pharma.AI platform. The proceeds will also fund ongoing global expansion and planned strategic initiatives, including a fully automated, AI-driven robotic drug discovery laboratory, and fully robotic biological data factory to complement Insilico’s vast curated data assets.

“Despite unprecedented market conditions in the biotechnology sector, we raised this Series D round from several of the most reputable US-based and global investors,” said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. “It is a testament to the strength of our end-to-end AI platform, which has been validated by many partners, and produced our first novel antifibrotic program discovered using AI and aging research, and designed using our generative AI chemistry engine. This unique program completed a first-in-human Phase 0 study in healthy volunteers and has entered Phase I clinical trials. We have also nominated seven preclinical candidates across a number of other disease indications since 2021. I am very excited about this progress and have decided to personally invest in this round.”

“The application of artificial intelligence and machine learning for drug discovery has incredible potential to transform the way new therapies are developed,” said Min Fang, Managing Director, Head of China Healthcare at Warburg Pincus. “For Insilico, 2022 was a year of incredible growth and progress. They have demonstrated the value of combining deep scientific expertise with cutting-edge technology capabilities to significantly accelerate drug discovery. We’re delighted to continue to partner with the Insilico team and support a company that is at the forefront of this innovation.”

Since the previous round of financing, Insilico has developed a growing portfolio in frontier areas empowered by its proprietary AI platform. Seven programs in its internal pipeline have progressed to the IND-enabling stage, including a novel 3CL protease inhibitor for COVID-19 treatment, and two synthetic lethality programs targeting MAT2A and USP1 for oncology. It also successfully completed a Phase 0 microdose study and entered a Phase I clinical trial with its first internally developed program targeting fibrosis.

“With the power of cutting-edge AI platforms developed fully in house and validated by many global pharmaceutical companies and our innovative, highly parallel, fully distributed drug discovery model, we nominated seven preclinical candidates since I joined the company in 2021,” said Feng Ren, PhD, Insilico’s Chief Scientific Officer and Head of Global Research and Development. “I have 15 years of experience working in large pharmaceutical companies and CROs and I am impressed by the speed and quality of our discovery programs. We plan to continue expanding the breadth of the pipeline and enhance our AI and robotics capabilities globally. Our rapidly growing team is composed of talented and experienced scientists in drug discovery with diverse backgrounds and relentless passion for novelty and innovation, and fully committed to developing novel drugs with a sense of urgency for the waiting patients.”

Insilico has also expanded its collaborations with the pharmaceutical industry through co-development and software licensing deals with a number of major pharmaceutical companies. Since the launch of its PandaOmics™ and Chemistry42™ in late 2020, nine out of the top 20 pharmaceutical companies have licensed Insilico’s AI platforms. In 2022, Insilico signed a multi-asset partnership deal with Fosun Pharma and EQRX in January, and a drug discovery co-development deal with EQRx in March. Notably, Insilico achieved its first major milestone and nominated a preclinical candidate for the QPCTL program for cancer immunotherapy in less than 40 days into the strategic collaboration with Fosun Pharma.




About Insilico Medicine

Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and to design novel molecular structures with desired properties. Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases and aging-related diseases.

#InsilicoMedicine #BCapitalGroup

News from Asia

Kenanga Investment Bank Highlights Collective Efforts Against Fraud in its 8th Annual Fraud Awareness Week

KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 20 November 2024 - Kenanga Investment Bank Berhad ("Kenanga" or "The Group") presents its eighth annual Fraud Awareness Week ("FAW"), highlightin...

The Establishment Agreement of the International Mangrove Center was signed in Shenzhen, China

SHENZHEN, CHINA - Media OutReach Newswire - 18 November 2024 - On November 6, 2024, the Establishment Agreement of the International Mangrove Center was officially signed in Shenzhen, Guangdong. R...

Generali Hong Kong Assigned ‘A’ Rating with ‘Stable’ Outlook by Fitch Ratings

HONG KONG SAR - Media OutReach Newswire - 20 November 2024 - Generali Life (Hong Kong) Limited ("Generali Hong Kong") has been assigned an Insurer Financial Strength (IFS) Rating of 'A' (Strong) b...

Jiangxi's Preservation of Ancient Streets and Villages Sparks a Surge in Cultural Tourism

NANCHANG, CHINA - Media OutReach Newswire - 20 November 2024 - On November 20th, the dance drama "Tian Gong Kai Wu," based on the legendary life of Jiangxi-born scientist Song Yingxing from the Mi...

CGTN: China to inject vitality into fair, equitable global governance system

BEIJING, CHINA - Media OutReach Newswire - 20 November 2024 - Nestled on the Red Sea coast of northwest Saudi Arabia, Neom, a brand-new metropolis, has reached a major milestone in its journey tow...

China's "Hainan Fresh Produce": Sweet Fruits 18°N Gaining Global Popularity

HAIKOU, CHINA - Media OutReach Newswire - 20 November 2024 - The northern hemisphere transitions into winter in November. In the southern end of Hainan Free Trade Port in China, Sanya City and Led...

DX design hub to Host Launching Party on 3 December, Open to the Public from 4 December

New Design Spot in Sham Shui Po Seeks to Nurture Creative and Design Talents, Foster Cross-Industry Collaboration and Exchanges A Creative Hub for Design and Fashion Inspiration HONG KONG SAR - ...

Results Of the Maire Foundation Study at COP29 In Baku: People in Azerbaijan and Kazakhstan Aware of The Urgency of The Energy Transition

MILAN/BAKU - Newsaktuell - 20 November 2024 – Awareness of the importance of the energy transition and the benefits that it can bring to the environment, the economy and society, is growing, includ...

SEAS unveils DigiLeap: AI-driven Decarbonisation Platform for Businesses supported by KPMG

DigiLeap is a first-of-its-kind AI-driven platform connecting over 200 enterprises, including financial institutions and technology providers, to expedite Singapore and ASEAN's trans...

OH!SOME Wins the FMCG Asia Awards 2024 for Global Membership Service System

Committed to Building a New Retail Membership System for the Southeast Asian Market JAKARTA, INDONESIA - Media OutReach Newswire - 20 November 2024 - The one-stop trendy retail brand OH!SOME has w...

5 Steps for Creating Effective Solutions to UX Problems

One of the most important components of any website or app is the design of the user experience (UX). Even the smallest UX issues need to be ident...

Business Training

Sydney Rain Bombs Could Be On The Increase

Motorway closures, forced evacuations, and flooding – Sydney has seen it all, including the recent weather event that has been dubbed the Taylor Swi...

Property

How Carolyn Creswell's Time Management Strategies Can Transform Your Workday

Carolyn Creswell, the mastermind behind Carman's Fine Foods, has not only revolutionised the food industry but also become a beacon of inspiration...

Business Training

Best Ways to Sell Real Estate Online

In today's digital age, selling property has never been easier or more convenient. With the vast array of online platforms and tools available, yo...

Property

Property peak urges re-elected Government to renew focus on real estate sector

The Real Estate Institute of Victoria (REIV) welcomed the Andrews Government’s Cabinet announcement today, congratulating The Hon. Danny Pearson M...

Property

5 most damaging blunders businesses are making

One of Australia’s leading online media agencies, Search Results, has released a list of the 5 most damaging blunders businesses are making today.   S...

Business Training